Back

Outcomes of edoxaban-treated patients with atrial fibrillation and concomitant vascular disease in daily clinical practice: insights from ETNA-AF-Europe

25 April 2021 (14:10 - 15:10)
Organised by:
Congress Presentation Part of: Prevention of stroke in atrial fibrillation Oral Anticoagulation EHRA Premium Access EHRA 2021

About the speaker

Photo
Doctor Tim Anthonie Christiaan de Vries

Amsterdam University Medical Centre (AUMC), Amsterdam (Netherlands (The))

6 More presentations in this session

Presentation thumbnail
Safety and effectiveness of edoxaban in a real-world clinical setting: Two-year follow-up of the ETNA-AF-Europe study
Professor J. De Groot (Amsterdam, NL)
Abstract Slides Video
Presentation thumbnail
Contemporary data evaluating 1-year clinical outcomes in patients with atrial fibrillation and coexisting valvular heart disease: the ETNA-AF-Europe study
Professor F. Ricci (Chieti, IT)
Abstract Slides Video
Presentation thumbnail
Off-label underdosed apixaban use in Asian patients with non-valvular atrial fibrillation
Doctor S. Lee (Seoul, KR)
Abstract Slides Video
Presentation thumbnail
Low bleeding and stroke rates with minor age-dependent increase confirm the safety and effectiveness of edoxaban in patients with atrial fibrillation across age groups: Two-year results from ETNA-AF
Doctor D. Morrone (Pisa, IT)
Abstract Slides Video
Presentation thumbnail
Annualized clinical event rates during two-year follow-up are low in 27,617 atrial fibrillation patients on edoxaban: results from the global noninterventional ETNA-AF program
Doctor L. Dinshaw (Wismar, DE)
Abstract Slides Video

Access the full session

Session thumbnail
Prevention of stroke in atrial fibrillation

The Event

Event poster

EHRA 2021

25 April 2021 14:10 CET
You may be interested in
thumbnail
Congress Session
Stroke prevention in clinical and subclinical atrial fibrillation
thumbnail
Congress Presentation
State-of-the-art lecture on stroke and bleeding risk in atrial fibrillation: walking the tight rope
thumbnail
Congress Session
Oral anticoagulation in subclinical atrial fibrillation

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources